FDA approves first triple-a-turalio (pexidartinib) for treatment of adult patients with symptomatic tendoncytoma

TGCT, also known as pigmentation fluffy conjure skateitis (PVNS), or tendon cytoblastoma (GCT-TS), is a rare non-malignant tumor with localized aggressionRecently, the U.SFDA(http://announced the approval of the first triamcinolone (http://company(http://developed by the set-up stimulator 1 receptor (CSF1R) inhibitor Turalio (pex1R) inhibitor Turalio (pexiedartinib) for the treatment of symptomatic tendonous cytoblastoma (TGCT) adult patientsPexidartinibPexidartinib is an innovative oral CSF1R small molecule inhibitorThe CSF1R-mediated signaling pathway is the main factor driving abnormal cell proliferation in the slip filmPexidartinib also inhibits the activity of c-kit and FLT3-ITDIt has been awarded by the FDA for breakthrough therapy and the eligibility of orphan drugsIn addition to its role in TGCT, CSF1R-mediated signaling pathways also play an important role in the differentiation and survival of mononucleosphages, especially macrophagesMacrophages in tumor microenvironments can promote tumor growth by suppressing immune responses and promoting angiogenesisPexidartinib inhibits the development of macrophages and is therefore also used in clinicaltrials(http://to treat other cancer types such as melanoma, prostate cancer, glioblastoma, classic Hodgkin's lymphoma, etcThe approval for enLIVENtheof thisnew drug(http:// is based on the results of a multi-center international Phase 3 clinical trial called ENLIVENA total of 120 patients were treated with either pexidartinib (n-61) or placebo (n-59)The results showed that 39 percent of patients treated with pexidartinib received remission after 25 weeks of treatment, compared with 0% in the placebo groupThe partial remission rate was 23% and the total remission rate was 15%in 23 patients who received remission, 22 patients were treated at least 6 months after the follow-up periodIn 13 patients who had at least 12 months of follow-up, the duration of remission was more than 12 months